Get the Stockscreener App
4.33
3.10%
0.13
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Oramed Pharmaceuticals Inc stock is traded at $4.33, with a volume of 193.50K.
It is up +3.10% in the last 24 hours and down -9.41% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
See More
Previous Close:
$4.20
Open:
$4.17
24h Volume:
193.50K
Relative Volume:
1.28
Market Cap:
$180.12M
Revenue:
$2.00M
Net Income/Loss:
$109.16M
P/E Ratio:
1.676
EPS:
2.5835
Net Cash Flow:
$-9.11M
1W Performance:
-3.56%
1M Performance:
-9.41%
6M Performance:
+23.01%
1Y Performance:
+82.70%
1-Day Range:
$4.15
$4.34
1-Week Range:
$4.15
$4.575
52-Week Range:
$2.09
$5.47
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.33 | 180.12M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Oramed Pharmaceuticals stock fell 3.74 percent as targets rose - AD HOC NEWS
Oramed Pharmaceuticals Inc (OJU1.DU) stock price, news, quote and history - Yahoo Finance Australia
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com Australia
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals (ORMP) CFO Avraham Gabay Sells 20,000 Sha - GuruFocus
Oramed COO & CBO Joshua Hexter sells $135,330 in shares By Investing.com - Investing.com Nigeria
Oramed COO & CBO Joshua Hexter sells $135,330 in shares By Investing.com - Investing.com South Africa
Form 4 Oramed Pharmaceuticals Inc For: 2 October By Investing.com - Investing.com India
Oramed COO & CBO Joshua Hexter sells $135,330 in shares - Investing.com
Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock - Investing.com
A planned CFO sale at Oramed Pharmaceuticals (ORMP) totals 20,000 shares at an average $4.51. - Stock Titan
Under a trading plan, Oramed (ORMP) COO Joshua Hexter sells 30,000 shares at $4.511 on average. - Stock Titan
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Nigeria
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Canada
An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan. - Stock Titan
A trading plan underpins an officer's proposed $140K share sale at Oramed (ORMP). - Stock Titan
40% of Oramed (ORMP) CFO’s stock award vests at grant; the rest vests over 24 months. - Stock Titan
Six option grants were canceled in exchange for a fully vested stock award to Oramed (ORMP) CEO Nadav Kidron. - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to S&P Global BMI Index - marketscreener.com
Oramed Pharmaceuticals stock trades quietly as investors weigh recent trial progress - AD HOC NEWS
Oramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Detailed Stock Data - The Chronicle-Journal
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com Nigeria
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com UK
Oramed Pharmaceuticals (ORMP) moves to three-year pay votes - Stock Titan
Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting - Investing.com
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Slips to $4.76, Holding Above $4.52 SupportIV Rank - careplusvn.com
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceConversion Trade - siam.in
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness - Yahoo Finance
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayMid-Term Outlook - dars.gov.et
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - Yahoo Finance
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - kalkine.ca
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oramed Pharmaceuticals Inc Stock (ORMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Avi Gabay | Officer |
Oct 01 '26 |
Proposed Sale |
4.67 |
20,000 |
93,400 |
0 |
| Hexter Joshua | COO & CBO |
Oct 01 '26 |
Sale |
4.51 |
30,000 |
135,330 |
1,328,130 |
| Joshua Hexter | Officer |
Oct 01 '26 |
Proposed Sale |
4.67 |
30,000 |
140,100 |
0 |
| Hexter Joshua | COO & CBO |
Jul 02 '26 |
Option Exercise |
3.69 |
50,000 |
184,500 |
1,073,384 |
| Hexter Joshua | COO & CBO |
Jul 01 '26 |
Sale |
4.46 |
137,000 |
611,431 |
1,023,384 |
| Gabay Avraham | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.51 |
73,360 |
330,744 |
671,785 |
| Hexter Joshua | Officer |
Jul 01 '26 |
Proposed Sale |
4.81 |
137,000 |
658,970 |
0 |
| Gabay Avraham | Officer |
Jul 01 '26 |
Proposed Sale |
4.81 |
93,360 |
449,062 |
0 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):